OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced it has received $1.9 million in non-dilutive funding to support its ongoing research and development programs. The funding will specifically accelerate the clinical development of urcosimod, OKYO's lead drug candidate for the treatment of Neuropathic Corneal Pain (NCP), a severely debilitating ocular condition with no FDA-approved treatments.

This non-dilutive capital strengthens OKYO Pharma's ability to execute on its development strategy without impacting existing shareholder equity. The funds will be used to advance key clinical milestones, expand R&D efforts, and build momentum behind urcosimod's regulatory pathway.

"This non-dilutive funding is a significant milestone for OKYO Pharma and allows the company to drive innovation and accelerate solutions that could improve patient outcomes," said Gary S. Jacob, PhD, CEO of OKYO Pharma. "Neuropathic Corneal Pain is a devastating and underdiagnosed condition with no approved therapies. These funds allow us to aggressively ...